Differences in Treatment Site of Care: Why Is My Insurer Sending Me to a Particular Treatment Center?December 07, 2018
This fact sheet discusses the differences in cost between cancer care at physician offices and health system-based sites of care.
This fact sheet describes the estimated rates of recurrence of selected cancers.
This fact sheet provides patient-focused information about the FDA drug approval process and guidance on researching FDA-approved agents for patients with cancer.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
The findings suggest that changes in genetic testing criteria are warranted.
A report highlights the current gap in the utilization of radiotherapy in Europe and outlines an action plan as a solution.
This fact sheet discusses the importance of palliative care as it pertains to cancer survivorship.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
This fact sheet discusses the research on supplement use and cancer incidence.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Disruptions in barrier integrity, use of corticosteroids, and use of intravenous antibiotics prior to chemotherapy may increase risk of febrile neutropenia.
To make informed treatment decisions, the affect a drug has on a patient's quality of life must be considered, investigators argued.
Integration of liquid biopsies will require understanding of their advantages and limitations.
A pleural adherence score derived from thoracic ultrasound at 24 hours post-talc administration is predictive of long-term pleurodesis success in patients with symptomatic malignant pleural effusion.
A draft guideline from the National Consensus Project for Quality Palliative Care describes best practices for caring for individuals who are seriously ill.
Health experts from around the world shared research at the 2018 World Cancer Congress. We recapped 5 key findings presented at the event.
This fact sheet discusses the risk of familial exposure to radiation during cancer treatment and strategies to help limit incidental contact with potentially harmful byproducts.
A recent Lancet Oncology Commission laid out why oncology and palliative care should be integrated and how to achieve successful integration despite barriers.
Is a higher frequency of organic food consumption correlated to a lower risk of cancer?
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Guidelines could help standardize the approaches used to conduct human intratumoral immunotherapy research.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
This in-depth review examines the inherent challenges of providing cancer care for incarcerated patients.
A suite of assays that rely on a single instrument and its related software could help researchers identify factors that drive immunotherapy response.
The TRK inhibitor larotrectinib continues to show efficacy in TRK-fusion cancers, regardless of patient age or cancer type.
More than half of patients with central nervous system metastases responded to the drug.
Few studies have evaluated the general exposure to plastics and cancer risk, and data on cancer risk among workers in the plastic industry are inconclusive.
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
There are no data on whether a vegan diet is an effective means of cancer prevention among high-risk populations.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer